Drugs / Neoantigen-based peptide vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06751901 | Mar 2024 → Mar 2026 overdue | non-small cell lung carcinoma | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06752044 | Sep 2024 → Aug 2026 overdue | non-small cell lung carcinoma | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| — | NCT06751966 | Sep 2024 → Aug 2026 overdue | colorectal cancer | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| — | NCT06751914 | Sep 2024 → Aug 2026 overdue | colorectal cancer | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen-based peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06752044 ↗ |
| Modality | Vaccine | “personalized tumor neoantigen-based peptide vaccine” NCT06751901 ↗ |
| Route | Subcutaneous | “10 subcutaneous injections of the vaccine within a treatment period of 21 weeks.” NCT06751901 ↗ |